Tasly Pharmaceuticals, Inc. Participated in Maryland Delegation at Asia’s Premier Biotechnology Partnering Event
Rockville, MD – October 17, 2022 – Tasly Pharmaceuticals, Inc. (“TPI”), a Maryland-based biopharmaceutical company, participated as an exhibitor at BioJapan 2022, an international partnering conference for the biotechnology and pharmaceutical industries, held in Yokohama, Japan, from October 12 to 14, 2022.
At the conference, TPI presented its research and development activities, with a focus on botanical drug development supported by clinical evaluation and translational research methodologies. The company’s work reflected industry trends emphasizing evidence-based approaches, real-world data integration, and multidisciplinary collaboration.
TPI also provided updates on T89 (Dantonic®), a botanical drug candidate that had completed a U.S. Food and Drug Administration (FDA) Phase III global clinical trial. The presentation included an overview of available clinical data and its development context.
Participation in BioJapan 2022 facilitated scientific exchange and supported the exploration of potential collaboration opportunities with international partners.
In addition to its pipeline targeting cardiovascular and neurological conditions, including persistent tic disorders, TPI engaged with potential partners in areas such as drug co-development, clinical research, and commercialization.
BioJapan 2022 was held at PACIFICO Yokohama (Hall B/C/D and Annex Hall North) from October 12 to 14, 2022, from 10:00 a.m. to 5:00 p.m. daily.
About Tasly Pharmaceuticals Inc.
Tasly Pharmaceuticals, Inc. is dedicated to advancing human health through safe and effective therapeutic solutions. The company focuses on the modernization of botanical medicines through scientific evaluation, including clinical and pharmacological research.
Founded in 2006 and based in Rockville, Maryland, TPI advances innovation in this field through scientific research, global collaboration, and integrated development initiatives.